Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study evaluated the 308-nm excimer laser as an adjuvant treatment for frontal fibrosing alopecia and found it may stabilize hairline recession and improve erythema and perifollicular hyperkeratosis, with transient erythema as the only reported adverse effect.

This study analyzed RSN complications in 18 hair transplantation patients and found that smoking, diabetes, and hypertension may increase risk, highlighting the need for prevention strategies and timely treatment.

In this case report, researchers highlight a 57-year-old HIV patient on ritonavir who developed Cushing’s syndrome from over-the-counter intranasal fluticasone, underscoring the risks of drug interactions and the importance of counseling patients about potential steroid ingredients in OTC products.

This study found that Flightless I (Flii) positively influences hair follicle regeneration in rodents, contrasting with its known negative effect on wound healing.

This report describes three cases of erythromelanosis follicularis faciei et colli showing significant improvement in facial telangiectasia following treatment with a 595-nm pulsed dye laser, with minimal recurrence observed during follow-up.

In this chapter, the authors provide a detailed overview of the fundamental science and operational principles of radiofrequency technologies, particularly in enhancing liposuction procedures through minimally-invasive techniques like RF-assisted lipolysis and fractional RF subdermal treatment.

This study found that oral administration of Flammulina velutipes polysaccharide reduced tumor volume and improved survival in mice by modulating macrophage polarization and enhancing antitumor immune responses.

This study found that intradermal QR678 Neo® therapy improved scalp condition in men and women with seborrheic dermatitis unresponsive to standard treatments, reducing flaking and inflammation after eight sessions, with high patient satisfaction reported.

This review discusses the current understanding of the epidemiology, pathogenesis, clinical manifestations, and diagnosis of female pattern hair loss and reports no new research results.

In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.

This study suggests that systemic oxidative stress in female pattern hair loss may be related to NRF2 deficiency, and NRF2 activators might assist in treatment.

This study found that daily treatment with ritlecitinib 50 mg over 24 months reduced the number of patients in the highest categories of scalp hair loss, with improvements seen in patient responses over time.

This study identified a new gene, mrp4, in mice, which suggests it may have a unique role in the growth and development of hair follicles in the ears and tails.

This study reports that riboflavin may increase enzymatic activity in a GCDH-deficient patient with specific mutations, but doesn't fully normalize urinary organic acid levels.

Certain peptides can prevent hair loss in young rats caused by a cancer drug.

This study highlights that topical ruxolitinib cream is FDA-approved for mild to moderate atopic dermatitis and nonsegmental vitiligo in patients aged 12 and older, but its use in other skin conditions like frontal fibrosing alopecia remains under-researched and needs further exploration in clinical practice.

This report discusses two cases where patients continued EGFR inhibitor therapy while receiving topical treatments for SDRIFE, highlighting the importance of dermatologists in managing such cutaneous adverse events without stopping cancer treatment.

This study assessed ritlecitinib's effects on sustained hair regrowth in patients with alopecia areata who showed improvement at 24 weeks, confirming ongoing benefits through 48 weeks for scalp, eyebrow, and eyelash hair regrowth in this post hoc analysis.

This review discusses the role of RDH12 in vision, its structural and functional aspects, and related disease mechanisms, but reports no new clinical results; it aims to support therapy development for inherited retinal dystrophies.

This study suggests that IV delivery of ExoFlo may be a safe and effective treatment for addressing symptoms in CRPS patients, warranting further investigation.

This study found that dysregulation of the folliculin-p0071 interaction may lead to changes in cell adhesion and signaling, contributing to conditions like emphysema and renal cell carcinoma.

This study reported that exposure to 1,763 MHz radiofrequency radiation stimulated hair growth in vitro by inducing insulin-like growth factor-1 expression in cultured human dermal papilla cells.

This study found that Arabidopsis thaliana mutants with altered AtRBOHC/RHD2 enzyme function showed abnormal protein regulation linked to increased drought sensitivity due to disrupted plasma membrane protein balance and cytoskeleton changes, as revealed through proteomic analysis and advanced microscopy.

This study found that a 30 Gy radiation dose was most effective in an experimental rabbit model of radiodermatitis, causing significant tissue changes and prolonged effects compared to lower doses and a control group.

In this case report, researchers observed that local radiation therapy to the orbits may not be sufficient to halt progression of new retinal lesions in older patients, even when the disease initially appears confined to the intraocular space.

This study reports that RU 58841-myristate, a new antiandrogen prodrug formulated with solid lipid nanoparticles, shows potential for targeting hair follicles in preclinical laboratory settings.

This clinical trial found that transdermal delivery of 5-Fluorouracil using fractional CO2 laser resulted in a significantly better treatment response in alopecia areata patients compared to intralesional injections of the same drug, with a greater reduction in the Severity of Alopecia Tool Score.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

In this study, low-dose naltrexone significantly reduced erythema in patients with frontal fibrosing alopecia and lichen planopilaris after one year, but no significant improvements were seen in other symptoms.